Announcements Trials
Browse Landscape

Status

Completed 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Blood Specimen Collection 17Surveys and Questionnaires 14Psychiatric Rehabilitation 7Therapeutics 6Polymerase Chain Reaction 5Interviews as Topic 5Immunohistochemistry 5Gene Expression Profiling 5Biopsy 5Radiotherapy 4Magnetic Resonance Spectroscopy 4High-Energy Shock Waves 4Reverse Transcriptase Polymerase Chain Reaction 3Microarray Analysis 3Fluorodeoxyglucose F18 3Abiraterone Acetate 3Watchful Waiting 2Standard of Care 2Specimen Handling 2Prednisone 2Methods 2Leuprolide 2In Situ Hybridization, Fluorescence 2Hematologic Tests 2Glucose Tolerance Test 2Drug Therapy 2Comparative Genomic Hybridization 2Chemotherapy, Adjuvant 2Biopsy, Fine-Needle 2Bariatric Surgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Observational × Triptorelin Pamoate × Clear all
NCT02588404 2024-12-10

The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

Sir Mortimer B. Davis - Jewish General Hospital

Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡